Piramal Pharma Solutions invests $10 M to expand its high potency API capability

Piramal Pharma Solutions (PPS), has invested $10 million for a new wing at the Riverview site dedicated to the production of high potency active pharmaceutical ingredients (HPAPIs) with low Occupational Exposure Levels (OELs).

The investment includes the new QC/analytical lab and two kilo-labs, as well as a doubling of the office space, which was needed to support the dramatic growth at the Riverview site.  Local dignitaries participated in the event, including Riverview Mayor Andrew Swift, Wayne County Executive Warren C. Evans and other officials representing the City of Riverview, Wayne County and Michigan Economic Development Corporation (MEDC).              

Vivek Sharma, CEO, Piramal Pharma Solutions said: “We are one of only a few companies in the contract development and manufacturing market that have the capability to produce HPAPIs at such low OELs. It’s another example of how we remain committed to partnering with our customers to serve the patient community and reduce the burden of disease.”

Vince Ammoscato, Vice President and Riverview Site Head, said: “This new, enhanced capability opens the site up to a new base of customers, including the antibody drug conjugate (ADC) market. We are equipped to offer ADC customers a seamless end-to-end solution, since we can develop the HPAPI payloads and linkers here in Riverview, send them to our site in Scotland for the antibody conjugation, then back to our Lexington, Kentucky site for sterile fill and finish.”